Aims: To measure the variation in prescribing of second-line non-insulin diabetes drugs.
prescribed an additional, second-line treatment. 2 The optimal drug choice after metformin is unclear, with four different treatments recommended by NICE to form a dual therapy with metformin: 5 sulphonylureas, pioglitazone (a thiazolidinedione [TZD] ), dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose co-transporter-2 (SGLT-2) inhibitors. The latter are recommended mainly if other therapies are contraindicated, but for the former three there is no particular order, and there is limited guidance on how they may be selected for different patients, except for some contraindications for pioglitazone.
For patients requiring further intensification, triple therapy should comprise metformin and one of three possible combinations of two of the aforementioned drugs, or a fifth class, glucagon-like peptide-1 (GLP-1) analogues, to be considered for obese patients.
Based on a sample of >400 000 people with type 2 diabetes on medication in 2013, 83.6% were receiving metformin, including 91.0%
of patients receiving their first treatment. 2 For patients requiring second-line therapy after metformin, 61.7% received a sulphonylurea and 26.9% a DPP-4; however, since then, SGLT-2 inhibitors have become available and 2015 NICE guidelines markedly departed from previous guidance which recommended sulphonylureas as preferred therapy after metformin.
It is unclear how this situation is evolving and whether the different available medications are offered to patients in a consistent manner across the country. There is wide variation in cost between these treatment options, with metformin and sulphonylureas costing an average of~£4 to £6 per item prescribed in 2015/2016, and SGLT-2 and DPP-4 inhibitors~£40 per item. 1 The aim of the present study was to determine variation in prescribing patterns and prescribing costs of antidiabetic treatments both geographically, across practices in England, and over time, by using three different datasets, summarized in Table S1 (Appendix S1).
| METHODS

| Data sources and preparation
We used 3 sources of data: the Clinical Practice Research Datalink (CPRD), a UK-representative database of anonymized primary care electronic health records; 6 annual Prescription Cost Analysis (PCA) data, aggregated nationally, covering 1998 to 2016; and monthly practice-level prescribing data, from September 2010 to August 2017.
| CPRD data
We extracted clinical and prescription records for 207 338 people with type 2 diabetes from the CPRD (download date January 19, 2017) who were prescribed a first-to fourth-line oral diabetes drug, classified in the BNF 6.1.2 as "other antidiabetic drugs," over the period 1998 to 2016 and had not previously been prescribed insulin.
A detailed description of CRPD data ascertainment has been previously reported. 7 Briefly, we positively identified patients with type 2 diabetes, largely on the basis of prescriptions rather than diagnostic medical codes because of known problems with coding errors 8 ; however, we excluded patients with diagnostic codes for other forms of diabetes (eg, steroid-induced, monogenic etc.) or polycystic ovary syndrome (which can be treated with metformin). Number of items represents the number of times each drug was prescribed; costs are NICs, which represent the basic price of the medicine, that is, the price listed in the Drug Tariff or published by the manufacturer or supplier. NICs may be subject to further charges and/or discounts. Costs were also corrected for inflation using the consumer price index compared with 2016. 12 
| Practice-level data
The monthly prescribing datasets published by NHS Digital contain one row for each treatment and dose, in each prescribing organization in NHS primary care in England, describing the number of prescriptions issued and the total cost. We limited this to organizations with setting code "4"-general practices, according to the NHS Digital dataset of practice characteristics, 13 to exclude all other organizations, such as prisons and out-of-hours services. Practices with a current status of "closed" or "dormant" were also excluded from the latest 12 months' analysis. Each practice in England belongs to one of 207 Clinical Commissioning Groups (CCGs) which are responsible for commissioning healthcare services in their local area, so we aggregated these data for CCG-level analyses. We used number of items, which represents the number of times each drug was prescribed, and actual costs, which are the full cost to the NHS including NICs and any further charges and discounts. 
| Prevalence data
| Extraction and classification of diabetes drug data
In the CPRD we categorized drug prescriptions using BNF codes and
Medcode keyword searches of "product name" and "drug substance name." The CPRD includes full prescription records but no data on drug dispensation. New drug prescriptions (and their corresponding start dates) were defined as the first-ever prescription of a drug in each class for each patient, even if only prescribed once. Patients were considered to have stopped a drug if there was a gap in prescribing of that drug of at least 6 months. 7 We defined first-, second-, third-or fourth-line prescription categories based on the order of new drug prescriptions for individual patients. Every time a patient started a new drug we assigned this to the next line of therapy, regardless of whether their concomitant therapy changed at a similar time point.
In the PCA and practice-level datasets we extracted the prescribing data for paragraph 6. (Table S2 , Appendix S1). In CPRD,
we assigned combination drug prescriptions containing metformin and one other to both constituent classes; in the PCA and practicelevel datasets these combination drugs were counted only as the nonmetformin drug (eg, metformin hydrochloride/rosiglitazone was assigned to the class of rosiglitazone, ie, TZDs). In all datasets, drugs containing a mixture of any other two classes were counted as "other."
| Analysis
We calculated prescribing rates per class of drug by dividing the num- for each available month and plotted as time trend charts using Python. After limiting to and aggregating the latest available 12 months, summary tables of CCG and practice prescribing were produced in Python.
| Maps
Maps of antidiabetic items prescribed by all CCGs in England for a single month snapshot were created using OpenPrescribing.net/analyse, by selecting all the chemicals within each class as numerator and BNF Paragraph 6.1.2 as denominator. The results were converted to percentages (from per 1000). The data source for OpenPrescribing.net is the monthly practice-level prescribing dataset described above. It includes all practices with status "4" (standard general practices), but does not exclude closed and dormant practices. The map of spend per patient across CCGs was produced using Tableau Open software.
| Data and code
PCA and practice-level data were extracted using SQL in Google 
| Prescription rates of second-, third-and fourthline diabetes therapies
The CPRD data show that metformin has been favoured as first GLP-1 analogues appear to be largely reserved for third-or fourth-line therapy only. Figure S1 (Appendix S1).
| Long term trends in prescribing for diabetes in England
| National variation in prescribing by CCGs
We investigated how the level of prescribing of each antidiabetic drug class varied across England, summarizing the proportions prescribed by each CCG over a 12-month period (Table 1 ) and mapping them geographically for a single-month snapshot (Figure 3 ). There was relatively low variation in metformin items as a proportion of all antidiabetic drugs (55.6% AE 2.9%; Table 1 and Figure 3 ), but more marked differences in the other available therapies favoured in each region. In the TZD class, the mean level of prescribing across CCGs was 2.5% AE 1.4% (Table 1) , but one CCG consistently prescribed more (12% in May 2017; Figure 3 ).
The spend on antidiabetic drugs per patient with diabetes over the latest 12 months ranged from £60 to £200 across CCGs ( Figure S2 , Appendix S1). Lower cost per patient generally corresponded to lower rates of prescribing of non-metformin, nonsulphonylurea classes ( Figure S2 , Appendix S1), but the variation in Abbreviations: DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; IQR, interquartile range; SGLT-2, sodium-glucose co-transporter-2; TZD, thiazolidinedione. Percentages represent the proportion of items for each drug class out of all anti-diabetic items prescribed (British National Formulary paragraph 6.1.2). The total number of items and cost of antidiabetic prescribing per patient are also given. SD and kurtosis for percentage measures are included as metrics of variation between regions. Table S4 (Appendix S1). DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; SGLT-2, sodium-glucose co-transporter-2; TZD, thiazolidinedione total prescribing level per patient (11.6 AE 2.0) may also be a contributor ( Table 1 ). The total spend was £414 m over this period; however, if every CCG could have prescribed at the lowest decile cost per patient (£95 per patient) this would represent a saving of £113 m, which is more than a quarter of the total costs for this area of prescribing.
| National variation in prescribing at practice level
As expected, variation was greater across practices than when aggregated to CCGs (Table S3 , Appendix S1); the proportion of metformin prescribed extended to a range of~40% to 70%, but with interquartile range restricted to 52% to 59%. This range of variation has remained roughly constant since 2010 (Figure 4) . Almost all practices prescribe at least some sulphonylureas and DPP-4 inhibitors, with interquartile ranges of 17.9% to 25.5% and 9.8% to 16.8% respectively. The remaining three classes are commonly prescribed in small proportions, with medians close to 0, and for 75% of practices they each make up <6% of antidiabetic medications (Table S3 , Appendix S1). The rise of the SGLT-2 inhibitor class is highly variable across practices ( Figure 4 ).
| DISCUSSION
We have assessed variation in NHS primary care prescribing of diabe- Correcting for diabetes prevalence allowed us to investigate variation in prescribing independently from the increasing number of people living with the condition. National type 2 diabetes prevalence data for 1998 to 2016 were extrapolated from estimates from THIN practices. 2 The advantage of these data is that the coverage of the sample is comprehensive, including secondary care data. The figures reported in the National Diabetes Audit (NDA) were lower, but prevalence in the NDA was lower than predicted from epidemiological studies because some patients were not registered as having diabetes by practices. 17 The QOF figures were~0.7 to 0.8 percentage points lower than the figures used, probably because the QOF includes all types of diabetes and excludes those aged <17 years, the age group with lowest prevalence; however, like the NDA, QOF data also depend on practice registrations which may be incomplete. QOF figures were the best available source of practice and CCG-level data on prevalence.
Similarly to the United Kingdom, type 2 diabetes guidelines from the American College of Physicians, the European Association for the Study of Diabetes and the American Diabetes Association all leave the choice of therapy after metformin largely to the practitioner [18] [19] [20] ; therefore, our key findings, that the use of therapy after metformin is changing dramatically and that there is geographical variation in drug prescribing in England, are likely to be generalizable to other countries.
We found that metformin has been favoured as first-line treatment since 2001, reflecting guidance and previous reports. 2 The rise in metformin use has been attributed to the publication of several UK-based studies on the efficacy of metformin from 1998, which had a high level of media publicity, with the later NICE guidance having no clear additional effect. 21 DPP-4 inhibitors are thought to have a similar efficacy to sulphonylureas but cause fewer side effects. 22 The increasing use of SGLT-2 inhibitors may relate to a favourable side effect profile in previous trials, which includes weight loss, oral admin- The relationship between type 2 diabetes prescribing levels and HbA1c control across practices participating in the NDA (>50%) has recently been studied. 25 Greater HbA1c control was quantities of blood testing strips and insulin used for people with type 2 diabetes). Greater achievement on non-pharmaceutical targets was also correlated with better HbA1c control. 25 Such variability in care and outcomes has led to the initiation of trials studying interventions targeted at primary care practitioners, including their prescribing behaviour. 26, 27 Previous work has shown that responses to unclear guidelines can be variable. When a common antipsychotic drug had its licence severely restricted but no specific advice was given on which alternative drug should be prescribed, in Scotland chlorpromazine was the most common replacement, whereas in England it was a combination of chlorpromazine and two newer drugs, 28 but regional variation within England was not studied. Similarly, the removal of the licence for co-proxamol was followed by an increase in several other analgesics. 29 In addition, while safety concerns around prescribing tend to be acted upon quickly, evidence-based guidelines have less impact, even when the prescribing advice is clear, suggesting that dissemination could be improved. 30, 31 We found unexplained variation in choice of non-metformin treatment, in the context of absence of clear advice in guidelines and current evidence. Aside from clinicians' personal choices, there may be a variety of external influences, including local policy, price changes, marketing, financial arrangements with drug companies, media reports, access to educational material, and drug safety alerts.
The present findings raise various prospects and opportunities in diabetes research. Firstly, they suggest that a randomized trial of choice of second-line medication would be clinically useful to resolve outstanding uncertainty on the best treatment for an extremely common clinical presentation. There is no such study ongoing in the United Kingdom, which seems a remarkable oversight, given that diabetes is the single biggest cost area for prescribing in NHS England. The one such study ongoing in the United States, GRADE, does not include SGLT-2 inhibitor therapy. 32 Secondly, the findings suggest that a pragmatic low-cost cluster randomized trial, randomizing practices or
CCGs to a prescribing policy that prefers a particular second-line treatment, would be justifiable on the grounds of costs and ethics, as there is already existing unexplained variation. 33 Thirdly, in the absence of guidance on which second-line treatment is best, and with guidance only suggesting that the lowest cost options within each class are preferred, we found extensive variation in prescribing costs between CCGs. The total spend was £414 m over 12 months, but with a potential saving of £113 m if all CCGs had prescribed at the same per-patient cost as the most efficient decile of CCGs; however, a full cost-effectiveness analysis would require consideration of differences in side effects and cardiovascular outcomes across the different drug classes as well as consideration of nonmedicinal treatments. Our OpenPrescribing.net project is an openly accessible data service which highlights prescribing variation in primary care, and allows practices and commissioners to monitor their own prescribing behaviour for key prescribing measures and any chemical of interest, using statistical process control techniques to send alerts automatically to practices when they deviate from national changes in behaviour (including on diabetes prescribing). We have previously argued that greater investment in disseminating evidence, auditing its implementation, and using variation in practice to target clinicians for educational interventions may all prove to be costeffective mechanisms to ensure that health services use treatments effectively and cost-effectively.
In conclusion, with a lack of good evidence to guide choice of second-line treatment for diabetes, we found evidence of extensive variation in choice of drug, and prescription volumes for new treatments rising as they appear on the market, in the absence of good comparative effectiveness data.
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